{"id":1068511,"date":"2024-04-09T13:01:11","date_gmt":"2024-04-09T17:01:11","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/cogent-biosciences-presents-data-highlighting-potential-best-in-class-potency-and-selectivity-of-novel-egfr-sparing-cns-penetrant-erbb2-inhibitor\/"},"modified":"2024-08-18T11:48:08","modified_gmt":"2024-08-18T15:48:08","slug":"cogent-biosciences-presents-data-highlighting-potential-best-in-class-potency-and-selectivity-of-novel-egfr-sparing-cns-penetrant-erbb2-inhibitor","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cogent-biosciences-presents-data-highlighting-potential-best-in-class-potency-and-selectivity-of-novel-egfr-sparing-cns-penetrant-erbb2-inhibitor.php","title":{"rendered":"Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor"},"content":{"rendered":"<p><![CDATA[IND-enabling studies expected to begin mid-2024 IND-enabling studies expected to begin mid-2024]]><\/p>\n<p>See the original post here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/04\/09\/2860059\/0\/en\/Cogent-Biosciences-Presents-Data-Highlighting-Potential-Best-in-Class-Potency-and-Selectivity-of-Novel-EGFR-Sparing-CNS-Penetrant-ErbB2-Inhibitor.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor\">Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the original post here: Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/cogent-biosciences-presents-data-highlighting-potential-best-in-class-potency-and-selectivity-of-novel-egfr-sparing-cns-penetrant-erbb2-inhibitor.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068511","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068511"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068511"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068511\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}